BRCA2 and breast cancer: Despite the lack of benefit in reducing BC incidence, it is interesting that the results show a benefit for BCSM, with one BC-related death prevented for every 5.6 and 14.5 RRSOs performed on BC-affected BRCA1 and BRCA2 carriers combined and BC-affected BRCA1 carriers alone, respectively.